global
gene
express
analysi
begin
move
laboratori
basic
investig
largescal
clinic
trial
potenti
technolog
improv
diagnosi
tailor
treatment
human
diseas
may
soon
realis
sever
comprehens
studi
demonstr
util
gene
express
profil
classif
tumour
distinct
clinic
relev
subtyp
predict
clinic
outcom
addit
new
data
emerg
proteom
platform
add
anoth
layer
molecular
inform
studi
human
diseas
scientist
attempt
catalogu
complet
inventori
protein
encod
genom
establish
biosignatur
profil
human
health
diseas
result
anticip
togeth
technolog
facilit
comprehens
studi
gene
gene
product
signal
pathway
object
personalis
molecular
medicin
achiev
paper
review
studi
best
demonstr
genom
proteom
technolog
use
improv
cancer
diagnosi
treatment
specif
highlight
import
work
incorpor
clinic
trial
cancer
research
made
signific
progress
identifi
new
molecular
taxonomi
cancer
use
genom
technolog
specif
use
dna
microarray
creat
robust
molecular
phenotyp
mani
tumour
includ
brain
breast
colon
gastric
kidney
leukaemia
lymphoma
lung
melanoma
ovari
prostat
small
round
bluecel
tumour
childhood
subset
studi
gene
express
profil
strongli
suggest
inform
would
improv
diagnosi
predict
clinic
outcom
compar
standardis
prognost
criteria
tumour
grade
tumour
size
patient
age
patient
perform
statu
recent
breakthrough
laboratori
qualifi
success
lack
standardis
method
data
collect
data
analysi
valid
howev
made
difficult
rigor
compar
studi
differ
laboratori
thu
hamper
introduct
type
data
clinic
medicin
fortun
microarray
field
propos
univers
standardis
guidelin
help
scientist
clinician
accur
compar
result
differ
laboratori
therebi
potenti
pave
way
use
gene
express
analysi
clinic
medicin
base
publish
work
va
nt
veer
et
al
van
de
vijver
et
al
netherland
cancer
institut
amsterdam
announc
januari
would
becom
first
institut
world
use
dna
microarray
analysi
make
treatment
decis
regard
women
breast
cancer
today
four
addit
institut
incorpor
gene
express
pattern
clinic
trial
breast
cancer
tabl
field
await
result
great
interest
encourag
earli
result
dna
microarray
technolog
inspir
develop
varieti
arraybas
platform
contribut
develop
systemwid
studi
protein
field
modern
proteom
tradit
twodimension
gel
electrophoresi
page
mass
spectrometri
basi
proteom
technolog
although
techniqu
provid
rich
inform
individu
protein
clinic
use
studi
proteom
limit
limit
techniqu
clinic
diagnost
primarili
due
low
sampl
throughput
compar
techniqu
addit
technic
challeng
relat
reproduc
gel
rel
low
number
protein
resolv
gel
limit
sensit
ie
low
abund
protein
easili
identifi
modern
proteom
technolog
discuss
sever
recent
review
develop
quickli
focus
mass
spectrometrybas
serum
pattern
profil
protein
microarray
continu
effort
discov
new
molecular
marker
therapeut
target
human
cancer
use
serum
proteom
pattern
analysi
creat
diagnost
signatur
ovarian
breast
prostat
liver
cancer
laboratori
patholog
nation
cancer
institut
nci
collabor
food
drug
administr
fda
proteomebas
strategi
use
earli
detect
ovarian
cancer
highrisk
women
preliminari
data
encourag
technolog
track
enter
clinic
trial
near
futur
women
live
spectr
aggress
diseas
ovarian
cancer
reliabl
screen
test
would
repres
major
step
forward
diagnost
capabl
physician
treat
integr
global
gene
profil
clinic
medicin
exemplifi
fact
earli
week
sever
acut
respiratori
syndrom
sar
pandem
center
diseas
control
sent
tissu
sampl
viral
cultur
sar
patient
dr
joseph
derisi
research
team
univers
california
san
francisco
explor
origin
novel
coronaviru
use
custom
oligonucleotid
dna
microarray
repres
virus
oligonucleotid
spot
array
patient
sampl
hybridis
group
eight
oligonucleotid
repres
two
viru
famili
coronavirida
astrovirida
although
identif
novel
coronaviru
associ
sar
made
use
broad
rang
laboratori
test
exampl
demonstr
power
microarray
technolog
molecular
diagnost
tool
test
spectrum
virus
singl
assay
narrow
finit
number
potenti
pathogen
unknown
diseas
nonspecif
clinic
present
admittedli
current
review
focus
genom
applic
cancer
exampl
deserv
special
mention
given
worldwid
attent
sar
moreov
illustr
exampl
integr
genom
analysi
tradit
clinic
histolog
assess
find
way
clinic
manag
va
nt
veer
et
al
van
de
vijver
et
al
express
data
breast
cancer
discuss
extens
sinc
announc
collect
two
group
begin
larg
clinic
trial
women
stage
iii
diseas
netherland
cancer
institut
upcom
trial
potenti
significantli
improv
current
breast
cancer
classif
system
influenc
treatment
origin
result
reproduc
much
larger
popul
women
first
studi
va
nt
veer
et
al
identifi
molecular
profil
gene
could
use
predict
patient
group
young
women
diagnos
stage
ii
breast
cancer
axillari
lymph
node
metastas
develop
distant
metastas
within
five
year
studi
gener
great
interest
implic
use
adjuv
treatment
patient
earli
stage
breast
cancer
current
statist
show
major
patient
stage
ii
breast
cancer
histolog
tumourfre
axillari
lymph
node
diseasefre
five
year
treat
breastconserv
surgeri
plu
patienttailor
therapi
review
review
radiat
therapi
mastectomi
current
recommend
therapi
localis
breast
cancer
unfortun
nearli
per
cent
women
treat
appropri
primari
breast
cancer
develop
metastat
diseas
thu
best
candid
adjuv
therapi
identifi
candid
use
current
clinic
criteria
howev
incred
difficult
recommend
nation
institut
health
nih
consensu
panel
intern
consensu
panel
st
gallen
confer
use
respect
prognost
predict
criteria
hereaft
collect
refer
convent
consensu
criteria
determin
elig
adjuv
therapi
advis
treatment
per
cent
patient
lymph
nodeneg
breast
cancer
va
nt
veer
colleagu
appli
express
profil
patient
cohort
studi
applic
allow
accur
differenti
lowrisk
highrisk
women
therebi
reduc
number
patient
would
ordinarili
advis
receiv
adjuv
treatment
per
centbas
convent
consensu
criteria
per
cent
valid
prognost
valu
express
profil
accur
predictor
risk
distant
metastas
van
de
vijver
et
al
studi
new
breast
cancer
tumour
includ
specimen
women
histolog
posit
axillari
lymph
node
current
nearli
women
posit
lymph
node
treat
type
adjuv
therapi
express
analysi
valid
studi
prove
accur
predictor
distant
metastas
within
five
year
convent
consensu
criteria
thu
improv
likelihood
identifi
patient
benefit
adjuv
therapi
specif
probabl
remain
metastasisfre
ten
year
per
cent
patient
classifi
goodprognosi
signatur
per
cent
patient
classifi
poorprognosi
signatur
addit
gene
express
profil
predict
surviv
overal
tenyear
surviv
rate
per
cent
patient
goodprognosi
signatur
per
cent
patient
poorprognosi
signatur
three
import
clinic
characterist
convent
consensu
criteria
associ
gene
express
profil
age
patient
histolog
grade
tumour
oestrogen
receptor
statu
note
one
wide
accept
prognost
factor
nodal
statu
associ
gene
express
profil
nodeposit
diseas
nodeneg
diseas
nearli
equal
distribut
two
group
dutch
team
readi
use
inform
trial
women
stage
ii
breast
cancer
decid
receiv
adjuv
therapi
preliminari
data
provid
excit
start
integr
genom
approach
clinic
demonstr
potenti
technolog
improv
diagnost
treatment
interest
learn
whether
gene
express
profil
valid
larger
group
women
given
express
profil
gener
young
women
year
age
median
age
diagnosi
breast
cancer
year
age
addit
anticip
make
treatment
decis
stage
ii
patient
breast
cancer
small
percentag
women
misclassifi
goodprognosi
signatur
ie
low
risk
develop
distant
metastas
receiv
adjuv
system
therapi
develop
metastas
within
five
year
although
misclassif
error
rate
significantli
higher
misclassif
rate
occur
today
use
best
clinic
criteria
avail
physician
work
done
technolog
introduc
clinic
without
deni
women
avail
treatment
upcom
studi
direct
daniel
haber
massachusett
gener
hospit
underscor
point
use
gene
express
profil
studi
decid
treatment
option
rather
valid
dutch
prognost
profil
lastli
interest
per
cent
tumour
goodprognosi
signatur
posit
gene
express
profil
studi
observ
statu
breast
tumour
strong
influenc
subsequ
classif
per
cent
tumour
poorprognosi
signatur
identifi
van
de
vijver
et
al
posit
howev
studi
requir
detect
addit
pathway
along
oestrogen
signal
pathway
determin
classif
addit
futur
proteom
data
breast
cancer
gene
express
analysi
may
help
identifi
addit
signal
pathway
import
good
prognosi
ovarian
cancer
diagnos
advanc
clinic
stagewhen
ovarian
cancer
cell
metastasis
ovari
pelvi
periton
caviti
distant
site
twothird
women
fiveyear
surviv
rate
latestag
patient
per
cent
despit
best
possibl
surgic
chemotherapeut
treatment
howev
ovarian
cancer
detect
still
confin
ovari
stage
treat
appropri
fiveyear
surviv
rate
optimist
per
cent
unfortun
earlystag
ovarian
cancer
difficult
detect
patient
frequent
asymptomat
reliabl
tumour
marker
exist
thu
develop
depend
serum
marker
earli
detect
ovarian
cancer
would
improv
surviv
rate
women
face
diseas
ncifda
clinic
proteom
program
proteom
approach
use
earli
detect
varieti
cancer
well
nonneoplast
diseas
infecti
diseas
autoimmun
diseas
vascular
diseas
prenat
diagnosi
transplant
reject
sever
clinic
trial
plan
includ
first
kind
ovarian
cancer
identif
specif
sensit
molecular
marker
epitheli
ovarian
cancer
prioriti
ncifda
clinic
proteom
program
tabl
propos
trial
potenti
develop
first
reliabl
screen
test
ovarian
cancer
protein
signatur
identifi
preliminari
studi
women
high
risk
develop
diseas
appli
screen
women
gener
popul
petricoin
et
al
use
mass
spectroscopi
coupl
artifici
intellig
comput
algorithm
develop
system
low
molecular
weight
serum
protein
profil
identifi
specif
protein
signatur
associ
ovarian
cancer
asymptomat
women
high
risk
develop
diseas
studi
serum
sampl
healthi
women
women
ovarian
cancer
use
train
set
identifi
serum
protein
signatur
specif
ovarian
cancer
valid
addit
unknown
serum
sampl
result
highli
accur
classif
patient
without
ovarian
cancer
per
cent
well
benign
diseas
per
cent
ovarian
cancer
per
cent
includ
stage
cancer
overal
result
yield
per
cent
sensit
per
cent
specif
identif
ovarian
cancer
posit
predict
valu
sampl
set
per
cent
compar
per
cent
serum
marker
sampl
signific
implic
ncifda
studi
serum
protein
signatur
accur
identifi
case
earlystag
ovarian
cancer
make
potenti
diagnost
tool
far
lack
clinic
laboratori
addit
studi
promis
creat
realist
opportun
clinic
manag
ovarian
cancer
gener
diagnost
mass
spectra
requir
small
serum
sampl
result
obtain
within
minut
costeffect
manner
press
goal
howev
valid
origin
result
larg
multiinstitut
clinic
trial
new
diagnost
tool
soon
avail
patient
physician
result
trial
import
better
understand
epitheli
ovarian
tumour
specif
molecular
protein
pathway
involv
develop
diseas
remain
unknown
hope
ad
serum
proteom
approach
current
screen
method
ovarian
cancer
translat
improv
diagnost
treatment
current
unpredict
aggress
cancer
anoth
goal
ncifda
clinic
proteom
program
use
protein
microarray
profil
function
state
signal
pathway
compris
protein
network
within
human
tissu
cell
figur
anticip
data
gener
studi
identifi
specif
signal
pathway
deregul
varieti
human
diseas
moreov
author
hope
understand
signal
pathway
facilit
develop
new
drug
target
specif
node
protein
circuitri
therebi
design
treatment
regimen
greater
efficaci
less
toxic
exampl
one
ongo
clinic
applic
nci
involv
phase
ii
clinic
trial
studi
type
iii
receptor
tyrosin
kinas
inhibitor
imatinib
mesyl
treatment
women
epitheli
ovarian
cancer
trial
biopsi
taken
primari
tumour
prior
initi
therapi
four
week
treatment
regimen
protein
microarray
use
determin
whether
receptor
tyrosin
kinas
pathway
activ
correl
clinic
efficaci
toxic
therapi
concept
premis
moleculartarget
therapi
similar
studi
involv
type
cancer
current
underway
nci
applic
serum
proteom
gene
express
analysi
earli
diagnosi
treatment
decis
daunt
challeng
requir
parti
practis
previous
dispar
disciplin
work
togeth
understand
data
may
form
clinic
inform
mathemat
algorithm
mass
spectrometri
challeng
clinic
proteom
dna
microarray
longer
develop
new
technolog
rather
best
use
integr
technolog
diagnosi
treatment
diseas
process
integr
repres
new
evolv
field
translat
medicin
